Looking for top-hit otoprotective compounds in your library?
Discover our fast and high-throughput in vitro screening assay to initiate your program in hearing disorders!
What can you do to prevent drug-induced hearing loss ?
Learn how to insulate your development program from ototoxicity
Watch the full video
MAKING HEARING A PRIORITY
CILcare is the world’s leading R&D services company committed to making hearing a priority. Take an in-depth look at how we can support your R&D program to prevent and treat ear disorders.
Discover our services
We are pleased to announce that Camille Dejean, Research Engineer at CILcare and PhD student in collaboration with the Institut Pour l'Audition and Pasteur Institute, will be at the Federation of European Neuroscience Societies' 2022 Forum on July 12th to give a...
CILcare to present results on ototoxic side effects of cancer and covid-19 treatments at NF Conference
We are pleased to announce that CILcare's Chief Scientific Officer, Sylvie Pucheu, PhD, will be at the Children Tumour Foundation's NF Conference in Philadelphia on June 19th to give a poster presentation on the ototoxic side effects of cancer and Covid-19 treatments....
For the second year in a row, CILcare will be sponsoring this event dedicated to inner ear therapeutics development to further act towards better treatments and innovation for those suffering from hearing disorders. Upcoming presentation: “Sensorineural Hearing...
Pharma / Biotech
CILcare, the world leading CRO dedicating to ear disorders
Because research & development in hearing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
CILcare proposes services to develop innovative solutions for hearing loss, tinnitus, otitis, and ototoxicity
Drugs to treat Hearing Loss and Tinnitus
Drugs and Medical Devices to treat Otitis
Medications safe for the ear (absence of ototoxicity)
Regenerative Therapies: Gene and Cell Therapies
Implantable Drug Delivery Devices and Imaging
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.
“CILcare is definitely more than a simple CRO! Following our work experience in PK/PD studies, CILcare now resonates as a trusted partner, fully committed to the success of their Sponsor’s assets. CILcare’s scientific expertise in the auditory system and neurosciences is no longer in doubt. The robustness of CILcare’s animal models, which highly mimic human ear disorders, gives us the confidence for translational success in clinical phases. It is always a pleasure to work with all the team members, they are very proactive, responsive, and dedicated to their customers.” Carmen Herrero, CSO, Spiral Therapeutics